SCHEMBL7040692

SCHEMBL7040692

COc1nn(-c2ccc(NS(=O)(=O)c3ccccc3Cl)cc2)c(=O)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.53
FAAH O00519 1/20 0.53
ABHD16A O95870 2/20 0.51
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
LPL P06858 1/20 0.49
LIPC P11150 1/20 0.49
LIPE Q05469 1/20 0.49
PGR P06401 1/20 0.47
PTPN2 P17706 3/20 0.45
PTPN1 P18031 3/20 0.45
PTPN5 P54829 3/20 0.45
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044319 0.82 ABHD16A (0.53) MGLLFAAHABHD16ALMNAMAPT
SCHEMBL7045584 0.81 PGR (0.58) MGLLFAAHABHD16ALMNAMAPT
SCHEMBL6601106 0.81 TP53 (0.62) MAPTTDP1ALDH1A1HDAC1
SCHEMBL6601531 0.77 ABHD16A (0.50) MGLLFAAHABHD16AMAPTLPL
SCHEMBL7040759 0.77 ABHD16A (0.58) MGLLFAAHABHD16ALPLLIPC
SCHEMBL7047556 0.77 MGLL (0.57) MGLLFAAHABHD16ALMNAMAPT
SCHEMBL6599976 0.76 LMNA (0.56) MGLLFAAHABHD16ALMNAMAPT
SCHEMBL2233406 0.74 ABHD16A (0.72) MGLLFAAHABHD16ALPLLIPC
SCHEMBL11620781 0.74 FAAH (0.78) MGLLFAAHABHD16ALPLLIPC
SCHEMBL7040851 0.73 FFAR1 (0.53) MGLLFAAHABHD16ALMNALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 MGLL 1542/4885FAAH 46/4885ABHD16A 1922/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE MGLL 10/4885FAAH 142/4885ABHD16A 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.